activation of integrin receptors
a novel therapeutic approach for treating kidney disease
ONT01
Enabling durable benefit and differentiates by targeting inflammatory cytokines and chemokines upstream of standard of care
- Focal segmental glomerulosclerosis (FSGS), diabetic kidney disease (DKD), lupus nephritis (LN) are chronic kidney diseases with limited treatment options and the potential to progress to dialysis, transplantation, and end-stage kidney disease.
- Currently treatments focus on broad immunosuppressive therapies, offering limited efficacy and substantial safety and tolerability risk.
- ONT01 enables durable benefit and differentiates by targeting inflammatory cytokines and chemokines upstream of standard of care
ONT01 blocks myeloid cell activation and kidney infiltration, offering a differentiated approach for treating FSGS, DKD, and LN
© 2025 Allosite Therapeutics. All rights reserved.